Arzneiverordnungs-Report 2017 2017
DOI: 10.1007/978-3-662-54630-7_3
|View full text |Cite
|
Sign up to set email alerts
|

Neue Arzneimittel 2016

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 125 publications
0
1
0
Order By: Relevance
“…Number of hospital admissions and readmissions per patient as well as per-patient costs for hospitalisation in € was determined by the recorded diagnosis-related groups codes used for reimbursement of inpatient medical services in Germany. The per-patient number of prescriptions of so-called follow-on drugs, patent-secured marginally altered pharmaceuticals with no benefit compared with the prototype drug according to evidence-based criteria,19 was determined by records of the central pharmaceutical numbers of prescribed medications (‘Pharmazentralnummer’). Outpatient medication costs per patient in € could be determined by accounting data for prescriptions reimbursed by the AOK state health insurance.…”
Section: Methodsmentioning
confidence: 99%
“…Number of hospital admissions and readmissions per patient as well as per-patient costs for hospitalisation in € was determined by the recorded diagnosis-related groups codes used for reimbursement of inpatient medical services in Germany. The per-patient number of prescriptions of so-called follow-on drugs, patent-secured marginally altered pharmaceuticals with no benefit compared with the prototype drug according to evidence-based criteria,19 was determined by records of the central pharmaceutical numbers of prescribed medications (‘Pharmazentralnummer’). Outpatient medication costs per patient in € could be determined by accounting data for prescriptions reimbursed by the AOK state health insurance.…”
Section: Methodsmentioning
confidence: 99%